𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Loss of lamivudine resistance mutations after patients switched to adefovir dipivoxil therapy

✍ Scribed by Christopher Westland; Craig Gibbs; Michael Miller; Mark Sullivan; John Fry; Carol Brosgart; Michael Wulfsohn; Shelly Xiong

Book ID
118564931
Publisher
Elsevier Science
Year
2002
Tongue
English
Weight
162 KB
Volume
36
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Increased risk of adefovir resistance in
Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy
✍ Yoon-Seon Lee; Dong Jin Suh; Young-Suk Lim; Suk Won Jung; Kang Mo Kim; Han Chu L πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 239 KB

Although adefovir dipivoxil (ADV) has a unique profile of delayed and infrequent resistance in treatment-naΓ―ve chronic hepatitis B patients, the association of ADV resistance with previous lamivudine (LAM) resistance is not well understood. We compared the emergence of the ADV-resistant mutations rt

Mutations associated with the therapeuti
Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis
✍ Kazuyoshi Ohkawa; Tetsuo Takehara; Michio Kato; Aimi Kanada; Matsuo Deguchi; Mas πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 269 KB

## Abstract Factors influencing the therapeutic efficacy of adefovir dipivoxil added to continuing lamivudine have not been elucidated in lamivudine‐resistant patients with type B chronic hepatitis. The viral mutations influencing the efficacy of treatment with adefovir dipivoxil were investigated